Regulatory momentum Leverage the FDA clearance and high-profile industry appearances to accelerate US market engagement with health systems, CROs, and pharma sponsors seeking digital biomarkers and remote monitoring. Position Hexoskin as an end-to-end platform combining wearable sensors, data analytics, and interoperability to support remote trials and post-market surveillance. Tailor outreach to procurement, regulatory, and clinical research teams highlighting validation and clinical relevance.

Open platform leverage The platform’s open interoperability enables seamless integration with EHRs, telemedicine networks, and research platforms, reducing integration risk for buyers. Target healthcare IT vendors, cloud platforms, CROs, and research networks for co-sell or integration partnerships, emphasizing a scalable data layer and AI-ready biomarkers.

Space and defense Hexoskin’s engagements with space agencies and aerospace/defense research underscore a compelling growth channel for extreme-environment monitoring. Explore partnerships with government programs, space agencies, defense contractors, and first-responder networks to deploy long-term wearable monitoring for remote operations and mission-critical health monitoring.

Wearable differentiation The wearable offers 100 percent washable, non-invasive ECG, lung function, and activity tracking suitable for chronic disease trials, sports science, and remote patient monitoring. Use cases include pharma sponsors and CROs running long-duration studies; emphasize reduced site visits, richer continuous data, and improved patient retention.

Growth engine Active fundraising and strategic collaborations signal speed and capacity to scale; DexMat CNT electrode partnership, HITLAB presence, and CSA contract illustrate momentum. Present Hexoskin as a scalable SaaS platform with expanding AI-driven biomarkers, inviting enterprise buyers and partners to co-create large-scale trials, space medicine initiatives, and global remote monitoring programs.